1. Home
  2. ALLO vs SB Comparison

ALLO vs SB Comparison

Compare ALLO & SB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • SB
  • Stock Information
  • Founded
  • ALLO 2017
  • SB 2007
  • Country
  • ALLO United States
  • SB Monaco
  • Employees
  • ALLO N/A
  • SB N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • SB Marine Transportation
  • Sector
  • ALLO Health Care
  • SB Consumer Discretionary
  • Exchange
  • ALLO Nasdaq
  • SB Nasdaq
  • Market Cap
  • ALLO 338.9M
  • SB 395.3M
  • IPO Year
  • ALLO 2018
  • SB 2008
  • Fundamental
  • Price
  • ALLO $1.44
  • SB $3.74
  • Analyst Decision
  • ALLO Strong Buy
  • SB Strong Buy
  • Analyst Count
  • ALLO 10
  • SB 1
  • Target Price
  • ALLO $9.66
  • SB $6.00
  • AVG Volume (30 Days)
  • ALLO 3.3M
  • SB 538.0K
  • Earning Date
  • ALLO 05-12-2025
  • SB 04-28-2025
  • Dividend Yield
  • ALLO N/A
  • SB 5.36%
  • EPS Growth
  • ALLO N/A
  • SB 36.11
  • EPS
  • ALLO N/A
  • SB 0.83
  • Revenue
  • ALLO $22,000.00
  • SB $307,633,000.00
  • Revenue This Year
  • ALLO N/A
  • SB N/A
  • Revenue Next Year
  • ALLO $8.30
  • SB $14.32
  • P/E Ratio
  • ALLO N/A
  • SB $4.51
  • Revenue Growth
  • ALLO N/A
  • SB 8.17
  • 52 Week Low
  • ALLO $1.30
  • SB $3.31
  • 52 Week High
  • ALLO $4.30
  • SB $6.33
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 36.16
  • SB 49.65
  • Support Level
  • ALLO $1.49
  • SB $3.64
  • Resistance Level
  • ALLO $1.69
  • SB $3.78
  • Average True Range (ATR)
  • ALLO 0.14
  • SB 0.08
  • MACD
  • ALLO -0.03
  • SB -0.01
  • Stochastic Oscillator
  • ALLO 17.50
  • SB 41.30

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About SB Safe Bulkers Inc ($0.001 par value)

Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.

Share on Social Networks: